- Informed choice on breast cancer screening: messages to support informed decision (KCE Reports 216)
- [Breast cancer screening with mammography for women in the agegroup of 40-49 years] (KCE Reports 129)
- Breast cancer screening amongst women aged 70-74 years of age (KCE Reports 176)
- [Identifying women at risk for breast cancer/technical methods for breast cancer screening] (KCE Reports 172)
- Oncogenetic testing and follow-up for women with familial breast/ovarian cancer, Li Fraumeni syndrome and Cowden syndrome (KCE Reports 236)
- Breast cancer in women: diagnosis, treatment and follow-up (KCE Reports 143)
- Survival and Quality of care offered in Belgian hospitals with and without recognition for breast cancer (KCE Reports 365)
- Quality indicators in oncology: breast cancer (KCE Reports 150)
- Gene expression profiling and immunohistochemistry tests for personalised management of adjuvant chemotherapy decisions in early breast cancer – a Rapid Assessment (KCE Reports 237)
- Trastuzumab in Early Stage Breast Cancer (KCE Reports 34)
- FDA withdraws accelerated approval of bevacizumab for the treatment of metastatic breast cancer (KCE has read for you)
- Autologous breast reconstruction techniques after mammary resection: time measurements for a potential reevaluation of the surgeon fee (KCE Reports 251)
- The right to be forgotten in breast cancer: new propositions (KCE Reports 351)
